Please assess the completion status of the following clinical trial:

Trial Title: Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CML in chronic phase (patients already on imatinib)~* Presence of Philadelphia chromosome or bcr-abl rearrangement~* Age ≥ 18 years~* ECOG performance status ≤ 2~* Written informed consent~Exclusion Criteria:~* Hepatic dysfunction (serum bilirubin ≥ 2 x ULN, and/or ALT ≥ 3 x ULN, and/or AST ≥ 3 x ULN)~* Renal dysfunction (creatinine ≥ 200 μmol/l or 2.3 mg/dl)~* Severe cardiac dysfunction (NYHA classification III-IV)~* Severe pulmonary or neurologic disease~* Pregnant or lactating females~* Patients with a history of active malignancy during the past 5 years with the exception of nonmetastatic skin cancer (e.g. treated squamous or basal cell carcinoma) or stage 0 cervical carcinoma~* Patients known to be HIV-positive~* Patients with active, uncontrolled infections~* Male and female patients of reproductive potential who are not practicing effective means of contraception~* Patients with known allergic reaction or intolerance to either imatinib or zileuton~* Patients requiring anticoagulation therapy with coumadin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm of experimental drug combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).